secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-028574
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio reports FY2025 net loss $1.40/sh; Phase 3 AD trial 65% enrolled
---------------------------------------------------------------------------

- FY2025 net loss $1.40 basic and diluted EPS; R&D $25.2M, G&A $4.5M; cash $19.5M expected to fund into Q3 2026.
- Phase 3 AD trial (NCT06709014) 65% enrolled across 83 US sites; DSMB positive recommendation at 6-month safety review.
- Open-label extension PD study initiated Jan 2026; FDA positive recommendation for PD dementia study design discussions.
- All patents transferred to new crystal form of buntanetap, extending IP protection to 2047.
- Appointed Mark Guerin as CFO and Hui Liu as Director of Biostatistics in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/0001104659-26-028574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/tm268976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer